NCT06250036 - Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

March 20, 2027

Study Completion Date

September 1, 2031

Conditions

Locally Advanced Gastric AdenocarcinomaMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction Cancer

Interventions

DRUG

Single agent zimberelimab

Single agent zimberelimab (PD-1 inhibitor) Q3W

DRUG

Combination zimberelimab + domvanalimab

Combination zimberelimab + domvanalimab (TIGIT inhibitor) Q3W

Trial Locations (9)

RECRUITING

Addenbrooke's Hospital, Cambridge

RECRUITING

Royal Devon University Healthcare Foundation Trust, Exeter

RECRUITING

Ninewells hospital and Medical School, Dundee

RECRUITING

Kent & Canterbury Hospital, Canterbury

RECRUITING

Guy's and St Thomas' NHS Foundation Trust, London

RECRUITING

The Royal Marsden NHSFT, London

RECRUITING

St James's University hospital, Leeds

RECRUITING

St Bartholomew's Hospital, London

RECRUITING

University College London Hospital NHS Foundation Trust, London